
Stoke Therapeutics STOK
$ 33.87
1.07%
Annual report 2025
added 03-16-2026
Stoke Therapeutics EV/EBITDA Ratio 2011-2026 | STOK
Annual EV/EBITDA Ratio Stoke Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.75 | -33.5 | -7.9 | -3.01 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.75 | -3.01 K | -764 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M | ||
|
Altimmune
ALT
|
-1.66 | $ 3.45 | 3.29 % | $ 304 M | ||
|
Amgen
AMGN
|
10.7 | $ 351.92 | 1.18 % | $ 189 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
17.3 | $ 19.55 | 0.26 % | $ 914 M | ||
|
I-Mab
IMAB
|
595 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
-1.38 | $ 1.4 | 1.82 % | $ 357 M | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-15.7 | $ 218.41 | -1.57 % | $ 5 B | ||
|
Aytu BioScience
AYTU
|
-1.92 | $ 2.61 | - | $ 16.4 M | ||
|
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | ||
|
Benitec Biopharma
BNTC
|
0.734 | $ 11.01 | 0.27 % | $ 453 M | ||
|
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - | ||
|
Compugen Ltd.
CGEN
|
-7.07 | $ 2.08 | -0.48 % | $ 194 M | ||
|
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | ||
|
Coherus BioSciences
CHRS
|
-4.11 | $ 1.59 | 4.28 % | $ 186 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
190 | $ 0.6 | -1.9 % | $ 6.87 M | ||
|
Cellectis S.A.
CLLS
|
-1.37 | $ 3.37 | 0.75 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
-8.81 | $ 12.91 | 1.33 % | $ 778 M | ||
|
Atreca
BCEL
|
-2.76 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-7.96 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
-6.7 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
0.0235 | - | -74.18 % | $ 955 K | ||
|
CorMedix
CRMD
|
-3.52 | $ 6.32 | 1.12 % | $ 455 K | ||
|
Checkpoint Therapeutics
CKPT
|
-0.833 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
-3.86 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | ||
|
Denali Therapeutics
DNLI
|
-14.1 | $ 20.96 | 3.92 % | $ 3.45 B | ||
|
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-3.41 | $ 4.26 | 0.35 % | $ 707 M | ||
|
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M |